Actively Recruiting
Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients
Led by ALPS Biotech CO. LTD · Updated on 2024-12-10
60
Participants Needed
1
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients. To investigate the advancements in neurodegenerative diseases.
CONDITIONS
Official Title
Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 30 to 70 years whose native language is Chinese
- Diagnosed with Spinocerebellar Ataxia
- Score below 30 on the Scale for the Assessment and Rating of Ataxia (SARA scale)
- Able to read, write, and communicate in Chinese
- Agree to participate in the study
You will not qualify if you...
- Severe systemic diseases such as heart or respiratory failure, liver or kidney failure, severe brain injury, prolonged bed rest, or incurable cancers
- Pregnant or breastfeeding women
- Use of Antrodia cinnamomea products within 6 months prior to the study
- Any other conditions preventing continued participation in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Cancer Center
Taipei, Taiwan
Actively Recruiting
Research Team
Y
Yu Hsuan Chang
CONTACT
I
Irene Tsai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here